Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders. Asset acquisition is projected to add approximately $6 million to $8 million of revenue in 2026 in a key gastroenterology market that leverages Merit’s existing commercial footprint. SOUTH JORDAN, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announ ...

Key Takeaways Hologic acquired Endomag to expand its breast surgery localization and tracing solutions.Endomag's products generated nearly $20M in Hologic's Q3 revenues with higher margins than legacy sales.Hologic's Interventional Breast segment topped $100M in sales, fueling its growth momentum.Over the years, Hologic’s (HOLX) Breast Health business has evolved, shifting from a heavily capital-focused approach to generating higher recurring revenues. While service revenues now exceed capital sales, the In ...

Core Insights - Avanos Medical, Inc. (AVNS) has acquired Nexus Medical, LLC to enhance its critical care offerings in nutrition and medication delivery, reinforcing its Specialty Nutrition Systems business [1][5] - The acquisition introduces Nexus Medical's TKO anti-reflux needleless connector technology, which aims to reduce blood reflux and associated risks during intravenous therapy, particularly in neonatal and pediatric care [2][8] - The deal is financed through existing cash reserves and is expected to be immediately accretive to revenue growth and earnings per share, positively impacting Avanos' financial profile [3][7] Financial Impact - The acquisition is anticipated to provide a near-term boost to Avanos' revenues and earnings, potentially improving investor confidence in the company's growth trajectory [5] - Avanos' shares have experienced a decline of 25.5% year-to-date, contrasting with an 11% decline in the industry and a 13.4% increase in the S&P 500 [4] Market Positioning - The addition of Nexus Medical's technology strengthens Avanos' competitive position in the critical care market, which is characterized by stable demand and high clinical importance [5][9] - The TKO connector aligns with the growing market demand for solutions that enhance patient safety and streamline clinical workflows, particularly in neonatal and pediatric care [8][9] - By integrating Nexus Medical's technology, Avanos aims to capture additional market share and broaden its critical care solutions portfolio, enhancing its overall competitiveness against larger medtech peers [9]

Core Viewpoint - The U.S. Federal Trade Commission (FTC) has moved to block JenaValve Technology's proposed acquisition by Edwards Lifesciences, which JenaValve intends to contest in court [1][2]. Company Overview - JenaValve Technology, Inc. is a medical device company focused on innovative transcatheter heart valve (THV) solutions for heart valve disease [3]. - The Trilogy THV System is designed for treating patients with symptomatic, severe aortic regurgitation (AR) and aortic stenosis, and has received CE Mark approval for dual-disease treatment capabilities in Europe [3]. - In the U.S., the Trilogy THV System is currently limited to investigational use only [3]. Company Locations and Backing - JenaValve is headquartered in Irvine, California, with additional locations in Leeds, United Kingdom, and Munich, Germany [4]. - The company is backed by several investment firms, including Bain Capital Life Sciences, Andera Partners, and Qatar Investment Authority (QIA) among others [4].